Gossamer Bio, Inc. (GOSS) Key Metrics

NASDAQ: GOSSValuation, returns, debt and efficiency ratios over 10 years.

GOSS valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$53.6M
Enterprise value
$50.0M
P/E (TTM)
—
Forward P/E
—
PEG ratio
—
Price / sales
1.0
Price / book
2.7
EV / EBITDA
—
Dividend yield
—
Beta
2.21

GOSS key metrics, 2016–2025

Fiscal year ended December 31, 2025 · U.S. dollars

GOSS valuation Price multiples at each fiscal year-end price.

Price / sales+718.8%
14.6
2025 · hover or tap a bar for each year
2024: 1.82025: 14.6 (+718.8%)
20162025
Free cash flow yield−22.5 pts
−24.2%
2025 · hover or tap a bar for each year
2023: −114.2%2024: −1.7% (+112.5 pts)2025: −24.2% (−22.5 pts)
20162025

GOSS valuation history

Fiscal year-endToday10-year median

GOSS returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

GOSS debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

GOSS price vs earnings per share

Share price at year-endEPS (right axis)

GOSS key metrics

2016–2025
Gossamer Bio, Inc. key metrics by fiscal year
2025202420232022202120202019201820172016
Valuation
Market capitalization$708.4M$204.7M$139.3M———————
Enterprise value$774.4M$113.1M$55.4M———————
Price / sales14.61.8————————
Price / book—6.92.2———————
EV / sales16.01.0————————
Earnings yield−24.0%−27.6%−129.0%———————
Free cash flow yield−24.2%−1.7%−114.2%———————
Shareholder yield (dividends + buybacks)—0.0%0.0%———————
Share price at fiscal year-end$248.00$72.40$73.04$173.60$904.80$773.60$1,250.40———
Per share
Revenue per share$16.97$40.56$0.00———————
Earnings per share−$59.64−$19.99−$94.26———————
Operating cash flow per share−$59.96−$1.23−$83.43———————
Free cash flow per share−$59.98−$1.23−$83.43———————
Cash per share$47.94$104.15$155.38———————
Book value per share−$42.98$10.43$32.90———————
Tangible book value per share−$42.98$10.43$32.90———————
Capex per share$0.03$0.00$0.00———————
Debt per share$71.03$71.74$111.37———————
Shares outstanding2.9M2.8M1.9M———————
Change in shares outstanding+1.0%+48.2%————————
Returns & profitability
Return on equity (ROE)—−122.5%−480.5%−343.5%−105.8%−72.3%−155.6%———
Return on assets (ROA)−69.9%−18.0%−61.5%−74.5%−53.0%−50.4%−54.3%−122.5%—−138.3%
Return on tangible assets−98.9%−17.9%−57.6%−84.2%−68.1%−45.1%−42.4%−61.4%—−138.3%
Free cash flow margin−353.5%−3.0%————————
Financial health
Total debt$202.9M$202.9M$212.5M$225.7M$185.2M$183.7M$39.5M—$6.0M$40,000
Cash & short-term investments$136.9M$294.5M$296.4M$255.7M$325.2M$512.6M$401.8M$228.7M$315,000$60,000
Net debt$66.0M−$91.6M−$84.0M−$29.9M−$140.0M−$328.9M−$362.2M−$228.7M$5.7M−$20,000
Debt / equity—6.883.3818.691.530.570.11———
Debt / assets1.180.640.680.830.540.340.09—13.570.67
Current ratio2.646.885.945.328.3213.5111.0911.370.350.42
Quick ratio2.646.885.945.328.3313.5011.1311.370.350.42
Interest coverage-14.9-5.2-13.6-15.7-11.1-16.6——-56.4—
Working capital$104.2M$264.9M$254.9M$212.7M$291.9M$483.7M$372.4M$211.6M−$821,000−$83,000
Invested capital−$56.8M−$62.1M−$21.2M−$17.9M−$18.5M−$8.2M−$9.7M−$348.7M−$1.1M−$143,000
Tangible asset value−$122.8M$29.5M$62.8M$12.1M$121.5M$320.7M$352.5M−$120.1M−$6.9M−$123,000
Net current asset value−$127.4M$24.1M$57.4M$1.5M$109.6M$303.6M$335.2M−$127.5M−$6.9M−$123,000
Graham net-net per share−$52.05$4.50$24.78———————
Capital allocation
Share buybacks (net)—$0$0$0$0$0$0$0——
Capex / revenue0.2%0.0%————————
Capex / operating cash flow—————————17,450.0%
Capex / depreciation0.080.000.000.110.315.832.1371.423.0342.05
Stock-based compensation / revenue21.8%18.0%————————
R&D / revenue359.2%120.7%————————
SG&A / revenue77.6%31.5%————————
Efficiency
Days sales outstanding67.317.0————————
Days of inventory on hand————8.1-48.5-177.2———
Days payables outstanding1,507.7344.9290.7193.8379.8361.9185.41,400.4——
Cash conversion cycle (days)-1,440.5-327.9————————
Receivables turnover5.4321.49——0.000.000.000.00——
Payables turnover0.241.061.261.880.961.011.970.260.000.00
Asset turnover0.200.370.000.000.000.000.000.000.000.00
Average receivables$8.9M$5.3M——$200,000$850,000$1.0M$500,000——
Average payables$4.1M$3.9M$3.5M$2.4M$5.4M$4.2M$1.6M$1.1M$68,500$40,000
Average inventory————$114,500−$567,500−$1.5M———
Intangibles / total assets0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Computed from GOSS's annual financial statements (latest annual report filed March 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

GOSS valuation and financial ratios

It ended the year with $202.9 million of debt and $136.9 million in cash and short-term investments, net debt of $66.0 million.

See the GOSS income statement, the GOSS chart for price history, or the GOSS stock overview for the latest quote and news.

GOSS key metrics FAQ

How much debt does Gossamer Bio have?

Gossamer Bio had total debt of $202.9 million at the end of fiscal 2025.

What is Gossamer Bio's free cash flow yield?

Gossamer Bio generated -$171.3 million of free cash flow in fiscal 2025, a free cash flow yield of −24.2% on its market value at year-end ($708.4 million).

What is Gossamer Bio's current ratio?

Gossamer Bio's current ratio was 2.64 at the end of fiscal 2025: current assets were 2.64 times current liabilities.

Biotechnology key metrics